Presentation type: Oral presentation at the Alzheimer’s Association International Conference 2025 in Toronto, Canada
Synopsis: An MRI-based machine learning model, trained to classify dementia types, was evaluated as a pre-screening tool in Alzheimer’s disease trials using A4 Study data. The model improved participant selection by predicting higher amyloid burden in AD cases, reducing screen failures and costs. IXICO’s advanced imaging analytics enable precision recruitment and operational efficiency for clinical trials.
Therapeutic Indication: Alzheimer’s disease (AD)
AI-Driven Recruitment for Alzheimer’s Disease Clinical Trials: A Pilot Analysis on the A4 Dataset
Date: 28th July 2025
Presentation type: Oral presentation at the Alzheimer’s Association International Conference 2025 in Toronto, Canada
Synopsis: embargoed
Therapeutic Indication: Alzheimer’s disease (AD)
Imaging - Advancing Biomarker Research for Alzheimer’s Disease Diagnosis
Presentation type: invited editorial in the Journal for Clinical Studies
Synopsis: editorial discussion on the multimodal use of PET imaging in combination with novel blood based biomarkers to support streamlined clinical trial delivery.
Therapeutic Indication: Alzheimer’s disease (AD)
AI-Driven Classification of Alzheimer’s Disease and Frontotemporal Dementia from Magnetic Resonance Imaging
Presentation type: co-authored journal manuscript with the TRACK-FA consortium in the Annals of Neurology Journal
Synopsis: development and validation of novel brain and spinal cord volumetric biomarkers for Friedreich’s Ataxia as part of the TRACK-FA study.
Therapeutic Indication: Friedreich’s Ataxia (FA)
The Potential of Blood-Based Biomarkers & Digital Assessments in Transforming Research and Clinical Practice
Date: February 26th 2025
Presentation type: invited podium presentation and discussion at the GAP-Net Site Optimization Conference 2025
Synopsis: invited presentation to discuss the critical role of imaging in an evolving AD biomarker landscape, specifically in combination with novel blood based biomarker tests. Joint panel with C-level experts from diagnostics and pharma companies.
Therapeutic Indication: Alzheimer’s disease (AD)
Comparison of two natural history studies as part of the HD-IH consortium: a use case for historical external control group matching in clinical trials
Presentation type: poster presentation at the 20th Annual HD Therapeutics Conference in Palm Springs, CA.
Synopsis: analysis of data from the HD-IH consortium to show that external control groups can support regulatory decision-making in clinical trials, especially rare diseases like Huntington’s disease (HD).
Therapeutic Indication: Huntington’s disease (HD)
Quantification Supports Amyloid PET Visual Assessment of Challenging Cases: Results from the AMYPAD Diagnostic and Patient Management Study
Presentation type: co-authored journal manuscript with the AMYPAD consortium in The Journal of Nuclear Medicine
Synopsis: analysis of the AMYPAD study data that shows how automated quantitative analysis of amyloid PET data can support and streamline visual expert assessment.
Therapeutic Indication: Alzheimer’s disease (AD)
A multi-stage approach to screen Amyloid status using plasma p-Tau217 prior to confirmatory Imaging applied to the Bio-Hermes Trial
Presentation type: oral presentation at the 17th Clinical Trials in Alzheimer’s Disease (CTAD) conference in Madrid, Spain.
Synopsis: analysis of the Global Alzheimer’s Platform Bio-Hermes data to investigate how blood-based-biomarkers can be operationalised in conjunction with PET imaging.
Therapeutic Indication: Alzheimer’s disease (AD)
Association of Vascular Risk Factors and Cerebrovascular Pathology with Alzheimer Disease Pathologic Changes in Individuals Without Dementia
Presentation type: co-authored journal manuscript with the AMYPAD consortium in the journal Neurology
Synopsis: investigation of links between vascular risk factors, cerebral small vessel disease, and amyloid levels and their combined effect on downstream AD biomarkers.
